1. Siegel RL, Miller KD and Jemal A: Cancer statistics. CA Cancer J Clin 68: 7-30, 2018.
2. World Health Organization, International Agency for Research on Cancer, Cancer Fact Sheets. http://gco.iarc. fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf, 2018 Accessed 4, September 2020.
3. Soslow RA: Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 27: 161-174, 2008.
4. Machida H, Matsuo K, Yamagami W, Ebina Y, Kobayashi Y, Tabata T, Kanauchi M, Nagase S, Enomoto T and Mikami M: Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO JSOG joint study. Gynecol Oncol 153: 589-596, 2019.
5. Lee AW, Navajas EE and Liu L: Clear differences in ovarian cancer incidence and trends by ethnicity among Asian Americans. Cancer Epidemiol 61: 142-149, 2019.
6. Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA and Aghajanian CA: Ovarian clear cell carcinoma, outcomes by stage: The MSK experience. Gynecol Oncol 139: 236-241, 2015.
7. Anglesio MS, Carey MS, Köbel M, Mackay H and Huntsman DG; Vancouver Ovarian Clear Cell Symposium Speakers: Clear cell carcinoma of the ovary: A report from the frst ovarian clear cell symposium, June 24th, 2010. Gynecol Oncol 121: 407-415, 2011.
8. Meyer T and Rustin GJ: Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82: 1535-1538, 2000.
9. Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, Mano Y, Yamamoto K and Nagata I: Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Gynecol Obstet Invest 47: 52-57, 1999.
10. Sierko E, Wojtukiewicz MZ and Kisiel W: The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost 33: 653-659, 2007.
11. Miyagi Y, Koshikawa N, Yasumitsu H, Miyagi E, Hirahara F, Aoki I, Misugi K, Umeda M and Miyazaki K: cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: Identifcation as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem 116: 939-942, 1994.
12. Rao CN, Reddy P, Liu Y, O'Toole E, Reeder D, Foster DC, Kisiel W and Woodley DT: Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor 2. Arch Biochem Biophys 335: 82 92, 1996.
13. Ogawa M, Yanoma S, Nagashima Y, Okamoto N, Ishikawa H, Haruki A, Miyagi E, Takahashi T, Hirahara F and Miyagi Y: Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intra- uterine growth restriction: Possible interaction and correlation with glypican-3 hold the key. Placenta 28: 224-232, 2007.
14. Karaszi K, Szabo S, Juhasz K, Kiraly P, Kocsis-Deak B, Hargitai B, Krenacs T, Hupuczi P, Erez O, Papp Z, et al: Increased placental expression of placental protein 5 (PP5)/tissue factor pathway inhibitor-2 (TFPI-2) in women with preeclampsia and HELLP syndrome: Relevance to impaired trophoblast invasion? Placenta 76: 30-39, 2019.
15. Rao CN, Lakka SS, Kin Y, Konduri SD, Fuller GN, Mohanam S and Rao JS: Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 7: 570-576, 2001.
16. Rollin J, Iochmann S, Bléchet C, Hubé F, Régina S, Guyétant S, Lemarié E, Reverdiau P and Gruelet Y: Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 92: 775-783, 2005.
17. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio Donahue CA, Eshleman JR and Gogginset M: Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adeno- carcinoma. Oncogene 24: 850-858, 2005.
18. Guo H, Lin Y, Zhang H, Liu J, Zhang N, Li Y, Kong D, Tang Q and Ma D: Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol 8: 110, 2007.
19. Nobeyama Y, Okochi-takada E, Furuta J, Miyagi Y, Kikuchi K, Yamamoto A, Nakanishi Y, Nakagawa H and Ushijima T: Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 121: 301-307, 2007.
20. Wong C, Ng Y, Lee JM, Wong CC, Cheung O, Chan C, Tung EK, Ching Y and Ng IO: Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45: 1129-1138, 2007.
21. Xu Y, Qin X, Zhou J, Tu Z, Bi X, Li W, Fan X and Zhang Y: Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma. Oncol Lett 2: 779-783, 2011.
22. Lavergne M, Jourdan ML, Blechet C, Guyetant S, Pape AL, Heuze-Vourc'h N, Courty Y, Lerondel S, Sobilo J, Iochmann S and Reverdiau P: Benefcial role of overexpression of TFPI 2 on tumour progression in human small cell lung cancer. FEBS Open Bio 3: 291-301, 2013.
23. Kempaiah P, Chand HS and Kisiel W: Human tissue factor pathway inhibitor-2 is internalized by cells and translocated to the nucleus by the importin system. Arch Biochem Biophys 482: 58 65, 2009.
24. Wang G, Zeng Y, Chen S, Li D, Li W, Zhou Y, Singer RH and Gu W: Localization of TFPI-2 in the nucleus modulates MMP-2 gene expression in breast cancer cells. Sci Rep 7: 13575, 2017.
25. Arakawa N, Miyagi E, Nomura A, Morita E, Ino Y, Ohtake N, Miyagi Y, Hirahara F and Hirano H: Secretome Based identifcation of TFPI2, A novel serum biomarker for detection of ovarian clear cell adenocarcinoma. J Proteome Res 12: 4340-4350, 2013.
26. Arakawa N, Kobayashi H, Yonemoto N, Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y, Hirahara F, et al: Clinical signifcance of tissue factor pathway inhibitor 2, a serum biomarker candidate for ovarian clear cell carcinoma. PLoS One 11: e0165609, 2016.
27. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing Haugen KL, Wicklund KG, et al: Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. Lancet Oncol 13: 385-394, 2012.
28. Cinti S, Matteis RD, Picó C, Ceresi E, Obrador A, Maffeis C, Oliver J and Palou A: Secretory granules of endocrine and chief cells of human stomach mucosa contain leptin. Int J Obes Relat Metab Disord 24: 789-793, 2000.
29. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz Ares L, Störkel S, et al: EGFR expression as a predictor of survival for frst line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 13: 33-42, 2012.
30. Wojtukiewicz MZ, Sierko E, Zimnoch L, Kozlowski L and Kisiel W: Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 90: 140-146, 2003.
31. Altmäe S, Salumets A, Bjuresten K, Kallak TK, Wånggren K, Landgren BM, Hovatta O and Stavreus Evers A: Tissue factor and tissue factor pathway inhibitors TFPI and TFPI2 in human secretory endometrium-possible link to female infertility. Reprod Sci 18: 666-678, 2011.
32. Zhai LL, Cai CY, Wu Y and Tang ZG: Correlation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinoma. Int J Clin Exp Pathol 8: 682-691, 2015.
33. Xu C, Wang H, He H, Zheng F, Chen Y, Zhang J, Lin X, Ma D and Zhang H: Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer. BMC Cancer 13: 118, 2013.
34. Sprecher CA, Kisiel W, Mathewes S and Foster DC: Molecular cloning, expression, and partial characterization of a second human tissue factor pathway inhibitor. Proc Natl Acad Sci USA 91: 3353-3357, 1994.
35. Wang G, Huang W, Li W, Chen S, Chen W, Zhou Y, Peng P and Gu W: TFPI-2 suppresses breast cancer cell proliferation and invasion through regulation of ERK signaling and interaction with actinin-4 and myosin-9. Sci Rep 8: 14402, 2018.
36. Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA and Gilks CB: A limited panel of immunomarkers can reliably distinguish between clear cell and high grade serous carcinoma of the ovary. Am J Surg Pathol 33: 14-21, 2009.
37. Huang W, Cheng X, Ji J, Zhang J and Li Q: The application value of HNF-1β transcription factor in the diagnosis of ovarian clear cell carcinoma. Int J Gynecol Pathol 35: 66-71, 2016.
38. Yamashita Y, Nagasaka T, Naiki Ito A, Sato S, Suzuki S, Toyokuni S, Ito M and Takahashi S: Napsin A is a specific marker for ovarian clear cell adenocarcinoma. Mod Pathol 28: 111-117, 2015.
39. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T and Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 22: 824-832, 2009.
40. The Human Protein Atlas: TFPI2. https://www.proteinatlas.org/ ENSG00000105825 TFPI2. Accessed April 8, 2020.
41. Vadivel K, Ponnuraj SM, Kumar Y, Zaiss AK, Bunce MW, Camire RM, Wu L, Evseenko D, Herschman HR, Bajaj MS and Bajaj SP: Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fbrinolysis. J Biol Chem 289: 31647-31661, 2014.
42. Rao CN, Cook B, Liu Y, Chilukuri K, Stack MS, Foster DC, Kisiel W and Woodley DT: HT 1080 fbrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer 76: 749-756, 1998.
43. Jin M, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Yasumitsu H, Miyazaki K, Nagashima Y, Aoki I and Miyagi Y: Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 83: 325-333, 2001.